CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Jan 15, 2025 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Sponsor
- BioAtla, Inc.
- Interventions being studied
- Biological: CAB-ROR2-ADC; Biological: PD-1 inhibitor
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Patients must have histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumor and have failed all available standard of care (SoC) therapy and for whom no curative therapy is available or who are not eligible, intolerant to or refuse standard therapy.
- Patients must have measurable disease.
- For the dose expansion phase: Patients with locally advanced unresectable or metastatic, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC) and soft tissue sarcoma (STS)
- Age ≥ 18 years.
- Adequate renal function
- Adequate liver function
- Adequate hematological function
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Life expectancy of at least three months.
- Patients must not have clinically significant cardiac disease.
- Patients must not have known non-controlled CNS metastasis.
- Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as wellas known or suspected allergy or intolerance to any agent given during this study.
- Patients must not have had major surgery within 4 weeks before first BA3021 administration.
- Patients must not have had prior therapy with a conjugated or unconjugated auristatin derivative/vinca-binding site targeting payload.
- Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.
- Patients must not be women who are pregnant or breast feeding.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Arizona Cancer CenterTucson, Arizona
- City of Hope - DuarteDuarte, California
- University of California, San Diego (UCSD) - Moores Cancer CenterLa Jolla, California
- California Research InstituteLos Angeles, California
- USC NorrisLos Angeles, California
- UC Irvine Medical Center - Chao Family Comprehensive Cancer CenterOrange, California
- University of California San FranciscoSan Francisco, California
- American Institute of ResearchWhittier, California
- University of ColoradoAurora, Colorado
- Sarah Cannon Research Institute at Health OneDenver, Colorado
- Florida Cancer Specialists & Research InstituteFleming Island, Florida
- Florida Cancer Specialists & Research InstituteFort Myers, Florida
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 15, 2025. Always confirm current availability with the study team.